The combination of pembrolizumab and the checkpoint inhibitor known as epacadostat is leading to promising responses and is generally well tolerated in patients with triple-negative breast cancer, non-small cell lung cancer, squamous cell cancer of the head and neck, and several other cancers, according to researchers.
from Top Health News – ScienceDaily http://ift.tt/2rkeeRP
from Tumblr http://ift.tt/2rBP41I
No comments:
Post a Comment